




RealRate

PHARMACEUTICAL 2016

Anthera Pharmaceuticals Inc
Rank 139 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Anthera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anthera Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Anthera Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 290%, being 26% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	47,862
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,468
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-2,638
Other Liabilities	0
Other Net Income	23
Other Revenues	3,185
Property and Equipment	263
Research and Development	33,498
Selling, General and Administrative Expense	7,568

Output Variable	Value in 1000 USD
Assets	48,125
Liabilities	8,468
Expenses	38,428
Revenues	3,185
Stockholders Equity	39,657
Net Income	-35,220
Comprehensive Net Income	-35,220
BaseVar	49,114
ECR before LimitedLiability	181%
Economic Capital Ratio	290%